Metagen Co., Ltd. Succeeded in predicting people who can improve bowel movements from bifidobacteria from intestinal environment information using machine learning

Metagen Co., Ltd.
Succeeded in predicting people who can improve bowel movements by bifidobacteria from intestinal environment information by using machine learning
~Toward personalized healthcare~

Metagen Co., Ltd. (Headquarters: Tsuruoka City, Yamagata Prefecture, President and CEO/CGDO: Shinji Fukuda, hereinafter “our company”) is a research group including Morishita Jintan Co., Ltd. (Headquarters: Osaka City, President: Yuji Morishita) Through joint research, we clarified the characteristics of the intestinal environment of “people whose bowel movements are improved by ingesting live bifidobacteria” using “metabologenomics (R)”. In addition, using machine learning, it was clarified that it was possible to predict the type of person whose bowel movements would be improved by ingesting bifidobacteria from the characteristics of the intestinal environment. The research results were published in the scientific journal “Computational and Structural Biotechnology Journal” on October 25, 2022.
[Image 1

-Research background-
Constipation caused by mental stress, changes in the living
environment, excessive diet, etc. is one of the symptoms that many people suffer from. In recent years, it has been reported that ingestion of fermented foods such as yogurt and probiotics such as bifidobacteria can improve bowel movements.
In particular, studies have continued to clarify the mechanism by which probiotic intake such as Bifidobacterium longum improves bowel movements, but it has also been found that the effect depends on the intestinal environment of the individual. In this study, we evaluated the improvement of bowel movement by ingestion of Bifidobacterium and examined whether it is possible to predict people who are expected to improve bowel movement based on intestinal environment information using machine learning.
-Summary of Research Results-
Twenty-four adults, mainly those with a tendency to constipation, were asked to take acid-resistant seamless capsules containing
bifidobacterium powder (hereinafter referred to as bifidobacteria) or a placebo containing starch in the same acid-resistant seamless capsules for two weeks. Bowel movements were evaluated, and intestinal flora and intestinal metabolites were analyzed. The four main results are:
Subjects who took bifidobacteria had a significant increase in the number of bowel movements after 2 weeks of administration compared to the placebo group.

[Image 2

Among the people who took bifidobacteria, there was a person whose defecation interval was remarkably improved. We defined those subjects as “responders” whose bowel movements were improved by ingestion of Bifidobacterium.
[Image 3

Using machine learning, we succeeded in predicting responders from the intestinal environment before ingestion of bifidobacteria. The gut bacteria of the responders were characterized by multiple types of intestinal bacteria, such as a large number of Eubacterium spp. and a low number of Dorea spp.

[Image 4

In the intestines of responders, it became clear that the amount of propionic acid and butyric acid tended to increase due to
bifidobacteria intake.
[Image 5

-Significance of research and future development-
In this study, we were able to predict subjects who are expected to be effective before ingesting bifidobacteria using machine learning. Recent research has revealed that there are individual differences in the efficacy of not only probiotics like this one, but also
pharmaceuticals. By further developing this research, it is expected that it will be possible to determine in advance whether food is effective or not based on information on the intestinal environment of an individual, leading to custom-made healthcare.
Going forward, we will continue to promote research and development that focuses on the stratification of the intestinal environment, and promote the development of products and services related to health maintenance and disease prevention that take into consideration the intestinal environment of each individual. We will continue to push forward.
-Reference Information-
Paper title:
Integrated gut microbiome and metabolome analyzes identified fecal biomarkers for bowel movement regulation by Bifidobacterium longum BB536 supplementation: A RCT.
author:
Yuya Nakamura[1,2], Shinya Suzuki[2,3], Shinnosuke Murakami[1,4], Yuichiro Nishimoto[1], Koichi Higashi[5], Naoki Watarai[2], Junpei Umetsu[2], Chiharu Ishii [4], Yutaro Ito[4], Yuka Mori[1], Mamiko Kohno[6], Takuji Yamada[1,2], and Shinji Fukuda[1,4,7-9]
Affiliation:
1 Metagen Co., Ltd.
2 School of Life Science and Technology, Tokyo Institute of Technology 3 Tokyo Institute of Technology Graduate School of Computational Life Sciences (ACLS)
4 Institute for Advanced Biosciences, Keio University
5 National Institute of Genetics
6 Morishita Jintan Co., Ltd.
7 Transborder Medical Research Center, University of Tsukuba 8 Kanagawa Prefectural Institute of Industrial Science and Technology (KISTEC) 9 Juntendo University Graduate School of Medicine
Publication magazine:
Computational and Structural Biotechnology Journal
volume 20 pp. 5847-5858, 2022
Publication date:
October 25, 2022
DOIs:
10.1016/j.csbj.2022.10.026
【Link destination】
https://www.sciencedirect.com/science/article/pii/S2001037022004731 [Inquiries regarding the release]
Metagen Co., Ltd.
〒997-0052
246-2 Minakami, Kakuganji, Tsuruoka City, Yamagata Prefecture Person in charge: Nishimoto, Nakaguro (Nakaguro)
E-mail: info@metagen.co.jp
TEL: 0235-64-0330
Details about this release:
https://prtimes.jp/main/html/rd/p/000000032.000051373.html


rehow

Leave a Reply

Your email address will not be published.

%d bloggers like this: